Stockscreener 앱 받기
8.33
4.69%
-0.41
전일 마감가:
$8.74
열려 있는:
$8.9
하루 거래량:
1.04M
Relative Volume:
1.44
시가총액:
$441.21M
수익:
$8.78M
순이익/손실:
$-104.70M
주가수익비율:
-3.5148
EPS:
-2.37
순현금흐름:
$-82.68M
1주 성능:
-22.00%
1개월 성능:
-15.00%
6개월 성능:
-43.72%
1년 성능:
+55.41%
1일 변동 폭
$8.20
$9.14
1주일 범위
$8.20
$11.11
52주 변동 폭
$5.21
$17.58
Stoke Therapeutics Inc Stock (STOK) Company Profile
명칭
Stoke Therapeutics Inc
전화
781-430-8200
주소
45 WIGGINS AVENUE, BEDFORD, MA
STOK을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
STOK
Stoke Therapeutics Inc
|
8.33 | 441.21M | 8.78M | -104.70M | -82.68M | -2.37 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-20 | 개시 | Chardan Capital Markets | Buy |
| 2024-10-14 | 재개 | Leerink Partners | Outperform |
| 2024-03-26 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-11-20 | 재개 | JP Morgan | Neutral |
| 2023-07-25 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-05-01 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2023-04-26 | 재개 | Canaccord Genuity | Buy |
| 2023-01-06 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2022-10-24 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2022-01-31 | 개시 | Jefferies | Buy |
| 2021-12-03 | 개시 | BofA Securities | Buy |
| 2021-11-22 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-05-18 | 개시 | UBS | Neutral |
| 2021-05-10 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-02-10 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2020-12-15 | 재개 | H.C. Wainwright | Buy |
| 2020-12-11 | 재확인 | Needham | Buy |
| 2020-10-23 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-09-29 | 재개 | JP Morgan | Neutral |
| 2020-09-29 | 개시 | Needham | Buy |
| 2019-12-18 | 개시 | Wedbush | Outperform |
| 2019-11-12 | 개시 | BTIG Research | Buy |
| 2019-10-25 | 개시 | H.C. Wainwright | Buy |
| 2019-07-15 | 개시 | Canaccord Genuity | Buy |
| 2019-07-15 | 개시 | Cowen | Outperform |
| 2019-07-15 | 개시 | Credit Suisse | Outperform |
| 2019-07-15 | 개시 | JP Morgan | Overweight |
모두보기
Stoke Therapeutics Inc 주식(STOK)의 최신 뉴스
Equities Analysts Offer Predictions for STOK Q1 Earnings - Defense World
HC Wainwright Has Bullish Forecast for STOK FY2025 Earnings - Defense World
Stoke Therapeutics (NASDAQ:STOK) and Tiziana Life Sciences (NASDAQ:TLSA) Head to Head Survey - Defense World
Trading (STOK) With Integrated Risk Controls - Stock Traders Daily
Stoke Therapeutics (NASDAQ:STOK) Earns “Buy” Rating from Chardan Capital - Defense World
Stoke Therapeutics’ Collaboration with BioGen - Global Legal Chronicle
Biogen and Stoke Therapeutics collaborates to develop Dravet syndrome treatment globally - MSN
Fenwick Represents Stoke Therapeutics in Strategic Collaboration with BioGen - Fenwick & West LLP
Biogen bags rights to epilepsy drug from Stoke in $550m deal - pharmaphorum
Stoke Therapeutics (NASDAQ:STOK) Shares Down 6.5% – Here’s Why - Defense World
Biogen and Stoke Therapeutics to commercialise Dravet syndrome treatment - Yahoo Finance
Stoke Therapeutics (NASDAQ:STOK) Given New $47.00 Price Target at HC Wainwright - Defense World
Stoke Therapeutics (NASDAQ:STOK) Receives Buy Rating from Needham & Company LLC - Defense World
Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments - BioSpace
Biogen takes territorial rights to Stoke’s Dravet program: Deals Report - BioCentury
Stoke Gets Runway, Biogen A Late-Stage Asset In Epilepsy Collaboration - News & Insights
Biogen’s Bold Bet: A New Hope for Dravet Syndrome Shines Bright - Smartphone Magazine
Biogen Strengthens Pipeline With Stoke Therapeutic's Dravet Syndrome Candidate Via Multi-Million Dollar Deal - Yahoo Finance
Biogen continues dealmaking buzz with Stoke Therapeutics - The Business Journals
Biogen buys rights to Stoke’s rare epilepsy drug - BioPharma Dive
Biogen Bets Up to $550 Million for Rights to Epilepsy Drug - Bloomberg
BTIG maintains Stoke Therapeutics stock with $29 target By Investing.com - Investing.com UK
HC Wainwright Adjusts Price Target on Stoke Therapeutics to $47 From $35, Maintains Buy Rating - Marketscreener.com
Biogen And Stoke Therapeutics Enter Into Collaboration -February 18, 2025 at 10:00 am EST - Marketscreener.com
Strategic Collaboration and Positive Clinical Data Propel Stoke Therapeutics to a Buy Rating - TipRanks
Biogen, Stoke Partner on Dravet Syndrome Investigational Drug Zorevunersen -February 18, 2025 at 09:39 am EST - Marketscreener.com
Biogen partners with Stoke Therapeutics to sell severe epilepsy drug - STAT
Biogen and Stoke Thera ink deal on zorevunersen development - The Pharma Letter
Biogen and Stoke Therapeutics collaborate to develop Dravet syndrome treatment globally - Seeking Alpha
Biogen, Stoke partner for Dravet syndrome treatment - Investing.com
Biogen, Stoke partner for Dravet syndrome treatment By Investing.com - Investing.com South Africa
Stoke Therapeutics and Biogen in pact for treatment for severe form of childhood epilepsy - MarketWatch
Biogen partners with Stoke Therapeutics on drug for severe epilepsy - STAT
Major Epilepsy Treatment Breakthrough: Biogen Acquires Rights to FDA-Designated Therapy in Massive Deal - StockTitan
Stoke Therapeutics: A Pivotal Moment For This RNA Pioneer - Seeking Alpha
Sector Update: Health Care Stocks Softer Wednesday Afternoon -February 12, 2025 at 01:47 pm EST - Marketscreener.com
SG Americas Securities LLC Sells 4,149 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Sector Update: Health Care Stocks Retreat Late Afternoon -February 12, 2025 at 03:54 pm EST - Marketscreener.com
Stoke Therapeutics (NASDAQ:STOK) Stock Price Down 9.7%Here's Why - MarketBeat
Long Term Trading Analysis for (STOK) - Stock Traders Daily
Understanding the 7.51% Volatility Levels of Stoke Therapeutics Inc’s (STOK) Stock in the Past 30 Days - The News Heater
STOK’s Stock Market Pendulum: Swinging Between Gains and Losses - The InvestChronicle
Stoke Therapeutics (NASDAQ:STOK) Stock Price Up 8.2%Here's Why - MarketBeat
Strength Seen in Stoke Therapeutics (STOK): Can Its 9.4% Jump Turn into More Strength? - MSN
Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives $21.29 Average Price Target from Analysts - Armenian Reporter
Stoke Therapeutics Inc (STOK) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News
Stoke Therapeutics Inc: Rising -28.33% from 52-Week Low, Can the Stock Stay Afloat? - The InvestChronicle
Trading Day Review: Stoke Therapeutics Inc (STOK) Gains Momentum, Closing at 12.60 - The Dwinnex
FY2025 Earnings Estimate for STOK Issued By Leerink Partnrs - MarketBeat
STOK (Stoke Therapeutics Inc) may reap gains as insiders became active recently - Knox Daily
Are Stoke Therapeutics Inc (STOK) shares a good deal now? - US Post News
Stoke Therapeutics Inc (STOK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Stoke Therapeutics Inc 주식 (STOK) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Skorpios Trust | 10% Owner |
Dec 23 '24 |
Sale |
11.50 |
2,000,000 |
23,000,000 |
6,906,181 |
0.27%
3.05%
자본화:
|
볼륨(24시간):